AMERICAN ACADEMY™
OF OPHTHALMOLOGY

QCDR Measure:

AAO-21: Ocular Myasthenia Gravis: Improvement of ocular deviation or absence of diplopia or functional improvement

National Quality Strategy Domain:

Effective Clinical Care

Measure Type:

Outcome

Description:

Percentage of patients with a diagnosis of ocular myasthenia gravis who had an improvement of ocular deviation OR were absent of diplopia in primary gaze OR had functional improvement of ptosis 6 months after initial treatment.

Instructions:

This measure is to be reported a minimum of once per reporting period for patients diagnosed with ocular myasthenia gravis between January 1 and June 30. It is anticipated that clinicians who provide the primary management of patients with ocular myasthenia gravis will submit this measure.

Denominator:

All patients aged 18 years or older diagnosed with ocular myasthenia gravis between January 1 and June 30 of the reporting period.

Denominator Criteria

Patients aged ≥ 18 years

AND

Diagnosis of ocular myasthenia gravis

- Myasthenia gravis without (acute) exacerbation (ICD-10: G70.00)
- Myasthenia gravis with (acute) exacerbation (ICD-10: G70.01)

Numerator:

Patients with improvement of ocular deviation or absence of diplopia in primary gaze after treatment or functional improvement of ptosis at 6 months

Numerator Options:

Performance Met:	Patients who had an improvement in ocular deviation 6 months after initial treatment. OR Patients who had absence of diplopia in primary gaze 6 months after initial treatment. OR Patients who had a functional improvement of ptosis 6 months after initial treatment.
Performance Not Met:	Patients who had no improvement in ocular deviation 6 months after initial treatment. OR Patients who had diplopia in primary gaze 6 months after initial treatment. OR Patients who did not have a functional improvement of ptosis 6 months after initial treatment.

Improvement Notation:

Higher score indicates better performance